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1. INTRODUCTION {#cam41939-sec-0001}
===============

As a novel class of endogenousnoncoding RNA, circular RNA (circRNA) generates from the back splicing by the canonical spliceosome.[1](#cam41939-bib-0001){ref-type="ref"} Rather than the line structure with a 5' cap or a 3' polyadenylated tail, circRNAs are characterized by a covalently closed loop structure.[2](#cam41939-bib-0002){ref-type="ref"}, [3](#cam41939-bib-0003){ref-type="ref"} Because of the stable and conserved characteristics, circRNAs are supposed to become required novel indicators and therapeutic targets for human cancers.[4](#cam41939-bib-0004){ref-type="ref"}, [5](#cam41939-bib-0005){ref-type="ref"} Moreover, circRNAs might be particularly expressed in a special cell line or developmental stage.[6](#cam41939-bib-0006){ref-type="ref"} The growing number of articles suggests that numerous functions of circRNAs including regulating transcription process and RNA splicing, functioning as microRNA sponges, and translation into different proteins which was processed by N6‐methyladenosine (m6A) modification.[7](#cam41939-bib-0007){ref-type="ref"}, [8](#cam41939-bib-0008){ref-type="ref"} However, more underlying mechanisms and functions of circRNAs remain largely unknown.

CircRNAs have been recently confirmed to have regulative functions in tumorigenesis, development of cardiovascular problems, and pathogenesis of neurodegenerative diseases,[9](#cam41939-bib-0009){ref-type="ref"} whereas the abnormal expression level and various functions of circRNAs in human hepatocellular carcinoma (HCC) remain largely unknown. HCC is the most common primary malignancy of the liver[10](#cam41939-bib-0010){ref-type="ref"} and one of the major causes of cancer‐related death worldwide, especially in China.[11](#cam41939-bib-0011){ref-type="ref"} For early‐stage HCC patients, surgical treatments including liver resection and transplantation are still the most curative treatment methods. Whereas taken the high incidence of postoperative recurrence into account, the prognosis after curative resection of HCC has remained unsatisfactory.[12](#cam41939-bib-0012){ref-type="ref"}

In our study, we performed a meta‐analysis to summarize the clinicopathological, prognostic, and diagnostic significances of circRNAs in HCC patients. Further prospective studies including more kinds of circRNAs are warranted in the future.

2. MATERIALS AND METHODS {#cam41939-sec-0002}
========================

2.1. Data search strategy {#cam41939-sec-0003}
-------------------------

A computerized literature search was performed in the PubMed, Scopus, Web of Science (WOS), EMBASE, and the Cochrane Library databases up to 17 July 2018. The search strategy of our study followed the terms such as: (a) "circRNA" or "circular RNA"; and (b) "liver cancer" or "liver carcinoma" or "liver tumor" or "hepatocellular carcinoma" or "HCC." Additionally, we hand‐searched the references of all relevant articles one by one if it is necessary. When the important data were not available, we tried to contact researchers of certain articles.

2.2. Inclusion and exclusion criteria {#cam41939-sec-0004}
-------------------------------------

The article selection used the following inclusion and exclusion criteria for each study.

A study that is eligible for inclusion must meet the following criteria: Case‐control study or cohort study including both case and control groups.Patients with a pathological diagnosis of HCC.Detection of circRNA expression level, clinicopathological features, and prognosis of patients.

Moreover, the exclusion articles all fitted the following criteria: Studies not relevant to circRNA or HCC.Similar studies or duplicate data in the different articles.Animal studies, reviews, case serious, expert opinions, letters.Without available data for analysis and the authors could not be contacted.Not English language.

2.3. Data extraction and quality assessment {#cam41939-sec-0005}
-------------------------------------------

Two investigators (Xin Huang and Weiyue Zhang) were assigned to assess the eligibility of all studies, and the relevant data for analysis were extracted on their own. Moreover, a third investigator (Zengwu Shao) resolved the disagreements when necessary. The important data were collected as follows: (a) baseline information of each study including author, year of publication, circRNA type, cancer type, case number, and detection method; (b) we extracted data involving upregulated and downregulated expression role of circRNAs, duration of follow‐up, and overall survival (OS) for prognosis analysis; (c) in diagnostic analysis, the sensitivity, specificity, and an area under the curve (AUC) were also collected; and (d) clinicopathological information including age, gender, tumor size, TNM stage, differentiation, vascular invasion, liver cirrhosis, lymphatic metastasis, distant metastasis, and so on. The study quality was assessed in accordance with the Newcastle‐Ottawa Scale (NOS) (Table [S1](#cam41939-sup-0005){ref-type="supplementary-material"}). The study was considered high quality with the scores were ≥7. Our study was in keeping with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement.

2.4. Statistical analysis {#cam41939-sec-0006}
-------------------------

The statistical data were analyzed by Stata version 14.0. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) wereutilized to evaluate clinicopathological parameters, sensitivity, and specificity, and hazard ratios (HRs) were to evaluate overall survival (OS). The chi‐square test and the *I* ^2^ statistic were utilized to assess the between‐study heterogeneity. If an *I* ^2^ value of \<50%, it was considered that no significant heterogeneity existed.[13](#cam41939-bib-0013){ref-type="ref"} A random‐effects model was utilized when there was a significant heterogeneity. Otherwise, the fixed‐effects model was used.[14](#cam41939-bib-0014){ref-type="ref"} We further made sensitivity analyses to detect the stability of results and the potential source of heterogeneity.[14](#cam41939-bib-0014){ref-type="ref"} Begg, Egger, and Deeks' tests were mainly used to assess the publication bias.[15](#cam41939-bib-0015){ref-type="ref"}

3. RESULTS {#cam41939-sec-0007}
==========

3.1. Search results {#cam41939-sec-0008}
-------------------

The study search is shown in the flow diagram (Figure [1](#cam41939-fig-0001){ref-type="fig"}). 81 relevant articles were collected during the database search. Furthermore, 48 were eliminated after abstract review, leaving 33 articles for further review. During the full‐text review, 16 studies were eliminated for the following reasons: 5 were not associated with circRNAs or HCC, 4 were without relevant data included, 3 were reviews, 1 was animal experiments, and 3 were of insufficient data for analysis. To sum up, 17 eligible studies with 1798 HCC patients were included in the present study. All the selected studies included 7 for clinicopathological features, 10 for prognostic analysis, and 8 for diagnostic analysis.

![Flowchart of the study selection process](CAM4-8-1148-g001){#cam41939-fig-0001}

3.2. Study characteristics {#cam41939-sec-0009}
--------------------------

The main features of each eligible study are summarized in details (Tables [1](#cam41939-tbl-0001){ref-type="table"} and [2](#cam41939-tbl-0002){ref-type="table"}). The years for publication ranged from 2017 to 2018. The range of sample size in each study was from 47 to 288. Moreover, the quantitative real‐time polymerase chain reaction (qRT‐PCR) was used to measure circRNA expression levels. As shown in Table [1](#cam41939-tbl-0001){ref-type="table"}, six types of circRNAs were recognized as tumor promoters and five were tumor suppressors. The range of mean duration of follow‐up was from 30 to 118 months. Moreover, the sensitivity, specificity, and AUC were extracted from eight studies for diagnosis analysis (Table [2](#cam41939-tbl-0002){ref-type="table"}). According to the Newcastle‐Ottawa Scale (NOS), the quality scores of all included studies ranged from 7 to 8, which indicated a high quality (Table [S1](#cam41939-sup-0005){ref-type="supplementary-material"}).

###### 

Main characteristics of studies for prognosis analysis

  Study         Year   CircRNA         Cancer type   CircRNA expression   Detection method   Regulation   Follow‐up (mo)   Citation   
  ------------- ------ --------------- ------------- -------------------- ------------------ ------------ ---------------- ---------- ------------------------------------------
  Xu et al      2017   circCdr1as      HCC           48                   47                 qRT‐PCR      Upregulated      62         [16](#cam41939-bib-0016){ref-type="ref"}
  Meng et al    2018   circ_10720      HCC           32                   65                 qRT‐PCR      Upregulated      118        [17](#cam41939-bib-0017){ref-type="ref"}
  Zhu et al     2018   circ_0067934    HCC           25                   25                 qRT‐PCR      Upregulated      60         [18](#cam41939-bib-0018){ref-type="ref"}
  Chen et al    2018   circ_0128298    HCC           39                   39                 qRT‐PCR      Upregulated      66         [19](#cam41939-bib-0019){ref-type="ref"}
  Huang et al   2017   circ_100338     HCC           29                   51                 qRT‐PCR      Upregulated      115        [20](#cam41939-bib-0020){ref-type="ref"}
  Zhang et al   2018   circSMAD2       HCC           43                   43                 qRT‐PCR      Upregulated      30         [21](#cam41939-bib-0021){ref-type="ref"}
  Han et al     2017   circMTO1        HCC           116                  116                qRT‐PCR      Downregulated    80         [22](#cam41939-bib-0022){ref-type="ref"}
  Zhang et al   2018   circ_0001649    HCC           35                   42                 qRT‐PCR      Downregulated    44         [23](#cam41939-bib-0023){ref-type="ref"}
  Guo et al     2017   circ‐ITCH       HCC           100                  188                qRT‐PCR      Downregulated    83         [24](#cam41939-bib-0024){ref-type="ref"}
  Zhong et al   2018   circC3P1        HCC           24                   23                 qRT‐PCR      Downregulated    60         [25](#cam41939-bib-0025){ref-type="ref"}
  Yu et al      2018   circ cSMARCA5   HCC           78                   85                 qRT‐PCR      Downregulated    60         [26](#cam41939-bib-0026){ref-type="ref"}

HCC, hepatocellular carcinoma; qRT‐PCR, quantitative real‐time polymerase chain reaction.

John Wiley & Sons, Ltd

###### 

Main characteristics of studies for diagnosis analysis

  Study            Year   CircRNA        Cancer type   Sample size   Method   Regulation   Diagnostic power   Citation                   
  ---------------- ------ -------------- ------------- ------------- -------- ------------ ------------------ ---------- ------- ------- ------------------------------------------
  Xu et al         2017   circCdr1as     HCC           48            47       qRT‐PCR      Upregulated        0.753      0.669   0.680   [16](#cam41939-bib-0016){ref-type="ref"}
  Chen et al (1)   2018   circ_0128298   HCC           39            39       qRT‐PCR      Upregulated        0.906      0.553   0.664   [19](#cam41939-bib-0019){ref-type="ref"}
  Chen et al (2)   2018   circ_0091582   HCC           39            39       qRT‐PCR      Upregulated        0.782      0.685   0.679   [19](#cam41939-bib-0019){ref-type="ref"}
  Chen et al (3)   2018   circ_0091528   HCC           39            39       qRT‐PCR      Upregulated        0.754      0.581   0.601   [19](#cam41939-bib-0019){ref-type="ref"}
  Guan et al       2017   circ_0016788   HCC           40            40       qRT‐PCR      Upregulated        0.923      0.756   0.851   [27](#cam41939-bib-0027){ref-type="ref"}
  Zhang and Zhou   2018   circ_0001445   HCC           55            44       qRT‐PCR      Downregulated      0.926      0.801   0.862   [28](#cam41939-bib-0028){ref-type="ref"}
  Fu et al         2017   circ_0004018   HCC           102           102      qRT‐PCR      Upregulated        0.716      0.815   0.848   [29](#cam41939-bib-0029){ref-type="ref"}
  Yao et al        2017   circZKSCAN1    HCC           102           102      qRT‐PCR      Downregulated      0.822      0.724   0.834   [30](#cam41939-bib-0030){ref-type="ref"}
  Shang et al      2016   circ_0005075   HCC           30            30       qRT‐PCR      Upregulated        0.833      0.900   0.940   [31](#cam41939-bib-0031){ref-type="ref"}
  Qin et al        2016   circ_0001649   HCC           89            89       qRT‐PCR      Downregulated      0.810      0.695   0.631   [32](#cam41939-bib-0032){ref-type="ref"}

AUC, area under the ROC curve; HCC, hepatocellular carcinoma; qRT‐PCR, quantitative real‐time polymerase chain reaction; Sen, sensitivity; Spe, specificity.

John Wiley & Sons, Ltd

3.3. Meta‐analysis for clinicopathological parameters {#cam41939-sec-0010}
-----------------------------------------------------

At first, we evaluated the relationship between circRNAs and clinicopathological parameters of HCC (Table [3](#cam41939-tbl-0003){ref-type="table"}). A significant association between high expression of oncogenic circRNAs and poor clinicopathological characteristics (tumor size: OR = 1.82, 95%Cl: 1.39‐2.38; TNM stage: OR = 2.07, 95%Cl: 1.51‐2.84; differentiation grade: OR = 1.89, 95%Cl: 1.48‐2.42; vascular invasion: OR = 1.83, 95%Cl: 1.34‐2.53; liver cirrhosis: OR = 1.52, 95%Cl: 1.17‐1.97; lymph node metastasis: OR = 2.83, 95%Cl: 1.77‐4.52; distant metastasis: OR = 3.50, 95%Cl: 1.51‐8.12; serum AFP: OR = 2.07, 95%Cl: 1.63‐2.64; HbsAg‐positive: OR = 1.65, 95%Cl: 1.24‐2.22) was observed in our study. Furthermore, our meta‐analysis showed that high expression of tumor‐suppressor circRNAs was significantly associated with better clinical parameters (tumor size: OR = 0.56, 95%Cl: 0.33‐0.96; TNM stage: OR = 0.68, 95%Cl: 0.58‐0.81; differentiation grade: OR = 0.69, 95%Cl: 0.56‐0.85; vascular invasion: OR = 0.48, 95%Cl: 0.32‐0.74), whereas there were no significant relationships between high tumor‐suppressor circRNAs expression and other clinicopathological parameters including age, gender, liver cirrhosis, serum AFP, and HbsAg‐positive.

###### 

Clinical characteristics of circRNAs in HCC

                                Tumor promoter   Tumor suppressor                                             
  ----------------------------- ---------------- ------------------ ----------- ----------- ----------------- -----------
  Age                           1.162            0.879‐1.537        0.291       0.973       0.732‐1.292       0.849
  Gender (M/W)                  0.921            0.790‐1.073        0.289       0.967       0.846‐1.104       0.615
  Tumor size                    **1.818**        **1.385‐2.387**    **0.000**   **0.564**   **0.331‐0.960**   **0.035**
  TNM stage (III + IV/I + II)   **2.073**        **1.512‐2.842**    **0.000**   **0.686**   **0.579‐0.811**   **0.000**
  Differentiation grade         **1.891**        **1.476‐2.422**    **0.000**   **0.691**   **0.559‐0.854**   **0.001**
  Vascular invasion (Y/N)       **1.837**        **1.335‐2.529**    **0.000**   **0.489**   **0.324‐0.738**   **0.001**
  Liver cirrhosis (Y/N)         **1.515**        **1.167‐1.965**    **0.002**   1.071       0.879‐1.305       0.497
  Lymph node metastasis (Y/N)   **2.830**        **1.773‐4.516**    **0.000**   NA          NA                NA
  Distant metastasis (Y/N)      **3.500**        **1.509‐8.116**    **0.004**   NA          NA                NA
  Serum AFP                     **2.071**        **1.627‐2.637**    **0.000**   0.958       0.784‐1.172       0.678
  HbsAg (P/N)                   **1.658**        **1.235‐2.226**    **0.001**   1.056       0.900‐1.240       0.503

The results are in bold if *P* \< 0.05.

CI, confidence interval; M, men; N, no/negative; NA, not available; OR, odds ratio; P, positive; W, women; Y, yes.

John Wiley & Sons, Ltd

3.4. Meta‐analysis for overall survival {#cam41939-sec-0011}
---------------------------------------

As shown in Figure [2](#cam41939-fig-0002){ref-type="fig"}A, oncogenic circRNAs overexpression was significantly correlated with a worse prognosis (OS: HR = 3.39, 95%Cl: 2.59‐4.19, *P* \< 0.001), and we adopted the fixed‐effect model because of no significant heterogeneity (*I* ^2^ = 34.6%, *P* = 0.191). Additionally, our study indicated that tumor‐suppressor circRNAs overexpression was related with improved survival (OS: HR = 0.46, 95%Cl: 0.37‐0.56, *P* \< 0.001). No significant heterogeneity (*I* ^2^ = 49.1%, *P* = 0.097) was observed, and the fixed‐effect model was used (Figure [2](#cam41939-fig-0002){ref-type="fig"}B).

![Forest plots for overall survival (OS) according to the type of (A) oncogenic circRNAs and (B) tumor‐suppressor circRNAs in HCC patients](CAM4-8-1148-g002){#cam41939-fig-0002}

3.5. Meta‐analysis for diagnosis analysis {#cam41939-sec-0012}
-----------------------------------------

Our study showed the forest plots of sensitivity and specificity for diagnosing HCC by circRNAs (Figure [3](#cam41939-fig-0003){ref-type="fig"}). Because the significant heterogeneity among studies existed (*I* ^2^ = 53.3% and *I* ^2^ = 56.1%), the random‐effect model was utilized. The following pooled outcomes were sensitivity (0.82, 95%CI 0.77‐0.86) and specificity (0.72, 95%CI 0.66‐0.77). Moreover, our study performed a summary receiver operator characteristic (SROC) curve (Figure [4](#cam41939-fig-0004){ref-type="fig"}) and calculated AUC (0.84, 95%CI 0.81‐0.87). In summary, our study suggested that circRNAs had a good diagnostic accuracy for HCC. Further studies were warranted to verify our conclusions.

![Forest plot of sensitivity and specificity of circRNAs for the diagnosis of HCC](CAM4-8-1148-g003){#cam41939-fig-0003}

![The summary receiver operator characteristic (SROC) curve](CAM4-8-1148-g004){#cam41939-fig-0004}

3.6. Publication bias and sensitivity analysis {#cam41939-sec-0013}
----------------------------------------------

Our study quantitatively performed Begg\'s and Egger\'s tests to assess publication bias among the eligible articles. There was no obvious publication bias according to Begg\'s test (*P* = 0.266) (Figure [S1](#cam41939-sup-0001){ref-type="supplementary-material"}) and Egger\'s test (*P* = 0.109) (Figure [S2](#cam41939-sup-0002){ref-type="supplementary-material"}). Therefore, we could exclude the possibility of publication bias. The sensitivity analysis revealed that the main outcomes of our study did not alter greatly when deleting studies one by one (Figure [S3](#cam41939-sup-0003){ref-type="supplementary-material"}). We conducted a Deeks' funnel plot asymmetry test[33](#cam41939-bib-0033){ref-type="ref"} with no obvious publication bias (*P* = 0.53) observed for diagnostic studies (Figure [S4](#cam41939-sup-0004){ref-type="supplementary-material"}).

4. DISCUSSION {#cam41939-sec-0014}
=============

The pivotal role of circRNAs in cancers was widely acknowledged in recent studies, whereas no relevant meta‐analysis on circRNAs expression in HCC existed. Our study indicated a significant relationship between high expression of circRNAs and clinicopathological, prognostic, and diagnostic significances in human HCC. Since the expression of circRNAs was upregulated or downregulated in HCC patients compared with normal tissues, we decided to recognize circRNAs as tumor promoters or tumor suppressors, respectively. 17 eligible articles including 7 for clinical parameters, 10 for prognosis, and 8 for diagnosis were included in our study. For clinicopathological features, oncogenic circRNAs overexpression was significantly related with worse clinicopathological characteristics and tumor‐suppressor circRNAs proved the contrary. In terms of the prognostic values, oncogenic circRNAs had a negative influence on overall survival, and tumor‐suppressor circRNAs overexpression was associated with longer survival periods. Moreover, the summary outcomes revealed the AUC of 0.84, with sensitivity of 82% and specificity of 72% for the diagnostic values of circRNAs expression in HCC.

The diagnostic significance of circRNAs as biomarkers for HCC was firstly evaluated by our study. The results revealed that circRNAs are appropriate as diagnostic biomarkers for HCC. Because the dysregulated expressions of circRNAs were detected successfully in cancer cells, tumor tissues, and even plasma samples from patients, it was convenient and inexpensive for us to get samples and have an examination. Moreover, the conserved and stable structures of circRNAs enabled them to be stable under whatever circumstances. To sum up, circRNAs might be important indicators for early diagnosis of HCC with great advantages.

With the aim of exploring the source of heterogeneity, we performed sensitivity analysis and found that none of those studies changed the results greatly. Neither the Egger test nor the Begg\'s funnel plot revealed obvious publication bias for clinicopathological and prognostic analysis. Furthermore, no evidence of publication bias in studies for diagnostic analysis existed according to the Deeks' funnel plot asymmetry test. Despite our reliable results, more relevant studies should be investigated to further confirm the findings of our study.

During the computerized study search, we found two previous meta‐analysis by Wang et al[4](#cam41939-bib-0004){ref-type="ref"} and Ding et al[34](#cam41939-bib-0034){ref-type="ref"} that detected the association between circRNAs and cancer. A great many differences existed among these studies. According to Wang et al, they highlighted the diagnostic value of circRNAs for human cancers especially in HCC diagnosis, whereas only five articles assessing the value of circRNAs in HCC patients were included. Ding et al assessed circRNAs as novel indicators in various tumors in fifteen articles. The pivotal role of circRNAs in HCC was not discussed. According to our study, a computerized literature search was performed and seventeen studies involving 1798 HCC patients were included. Moreover, we assessed both prognostic and diagnostic significances of circRNAs expression in HCC patients. Nevertheless, larger‐scale and higher‐quality studies conducted by multicenters were warranted to further confirm these findings.

Whereas, several limitations should be acknowledged in the present study. Firstly, because of limited number of articles, we failed to perform a subgroup analysis in terms of different circRNAs. Secondly, functional studies associated with underlying mechanisms of circRNAs in the tumorigenesis are needed. Thirdly, the relatively small number of patients might bring about the insufficiency of statistical power.[14](#cam41939-bib-0014){ref-type="ref"} Finally, several HRs outcomes were not available in the studies directly. Accordingly, HRs were extracted from the Kaplan‐Meier curves or calculated in accordance with the method of Parmar et al.[35](#cam41939-bib-0035){ref-type="ref"} However, it may introduce potential source of bias.

In conclusion, our study revealed a significant relationship between high expression of circRNAs and clinicopathological, prognostic, and diagnostic values in HCC patients. Additionally, circRNAs may be novel biomarkers and therapeutic targets for HCC. More studies are warranted to investigate the value of circRNAs in HCC patients for years to come.
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